Anti‐CD20 therapy of treatment‐resistant Wegener's granulomatosis: favourable but temporary response
- 1 June 2005
- journal article
- case report
- Published by Informa UK Limited in Scandinavian Journal of Rheumatology
- Vol. 34 (3), 229-232
- https://doi.org/10.1080/02813430510015269
Abstract
Rituximab is a genetically engineered chimeric monoclonal immunoglobulin (Ig)G1 antibody. It binds the CD20 trans‐membrane surface antigen expressed by mature B cells but not by antibody secreting plasma cells, and removes the cells by activating complement, inducing cell‐mediated lysis, and by apoptosis 1, 2. Mainly used for the treatment of non‐Hodgkin's lymphomas, rituximab has recently been tried with favourable responses in rheumatoid arthritis, systemic lupus erythematosus, and other chronic immunological diseases 3–6. Wegener's granulomatosis (WG) is a granulomatous vasculitis with high morbidity and mortality 7, 8. It is thought that anti‐neutrophil cytoplasmatic antibodies (ANCA) with specificity for proteinase 3 (PR3) are possibly involved in the pathogenesis of the disease 9, 10. Conventional therapy with cyclophosphamide and corticosteroids generally succeeds in inducing remission, but relapses frequently follow. Among the biological agents, tumour necrosis factor‐α (TNF‐α) inhibitors have been tried with some success 11. Based on a case report 12 we recently treated three refractory WG patients with rituximab and achieved almost complete but temporary remission. CD20+ cells disappeared rapidly in peripheral blood, only to rise prior to subsequent disease flares occurring at 34, 63, and 54 weeks, respectively (Figure 1). A new flare occurred in one patient at 86 weeks. At the end of the observation periods (54, 102, and 120 weeks), only one patient had proteinuria. Chest radiographs became normal in two patients, while infiltrates remained unchanged in the third. Granulomatous retro‐orbital or sinus masses in two patients seemed unresponsive to therapy.Keywords
This publication has 12 references indexed in Scilit:
- Prospective Study of TNFα Blockade with Infliximab in Anti-Neutrophil Cytoplasmic Antibody-Associated Systemic VasculitisJournal of the American Society of Nephrology, 2004
- Neutrophil Membrane Expression of Proteinase 3 (PR3) Is Related to Relapse in PR3-ANCA-Associated VasculitisJournal of the American Society of Nephrology, 2002
- In vitro cytokine production and proliferation of T cells from patients with anti‐proteinase 3‐ and antimyeloperoxidase‐associated vasculitis, in response to proteinase 3 and myeloperoxidaseArthritis & Rheumatism, 2002
- Anti‐CD20 monoclonal antibody (Rituximab) for life‐threatening autoimmune haemolytic anaemia in a patient with systemic lupus erythematosusBritish Journal of Haematology, 2002
- Complement activation plays a key role in the side‐effects of rituximab treatmentBritish Journal of Haematology, 2001
- Wegener's granulomatosis: clinical course in 108 patients with renal involvementNephrology Dialysis Transplantation, 2000
- Pathogenesis of ANCA-associated systemic vasculitisThe Journal of Pathology, 2000
- Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20Blood, 1994
- Wegener Granulomatosis: An Analysis of 158 PatientsAnnals of Internal Medicine, 1992
- Antigen-specific interaction between T and B cellsNature, 1985